TransMedics Group (NASDAQ:TMDX) Upgraded to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of TransMedics Group (NASDAQ:TMDX) from a hold rating to a buy rating in a research report sent to investors on Saturday morning.

Several other brokerages also recently commented on TMDX. Morgan Stanley lifted their target price on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Needham & Company LLC raised their price target on TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Piper Sandler reissued an “overweight” rating on shares of TransMedics Group in a research report on Monday, December 22nd. Finally, Canaccord Genuity Group raised their target price on TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, TransMedics Group presently has an average rating of “Moderate Buy” and an average price target of $144.25.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $129.84 on Friday. The stock has a market capitalization of $4.44 billion, a P/E ratio of 52.57 and a beta of 2.06. The business has a 50-day moving average of $132.32 and a two-hundred day moving average of $125.42. TransMedics Group has a fifty-two week low of $62.07 and a fifty-two week high of $156.00. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13.

Insider Buying and Selling

In other TransMedics Group news, CFO Gerardo Hernandez sold 920 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $139.62, for a total value of $128,450.40. Following the completion of the sale, the chief financial officer owned 15,064 shares in the company, valued at approximately $2,103,235.68. This trade represents a 5.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Anil P. Ranganath sold 3,000 shares of TransMedics Group stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total value of $435,660.00. Following the sale, the insider directly owned 13,955 shares in the company, valued at $2,026,545.10. The trade was a 17.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 8,920 shares of company stock valued at $1,257,310 over the last three months. 7.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On TransMedics Group

Hedge funds have recently made changes to their positions in the business. Whittier Trust Co. of Nevada Inc. increased its stake in TransMedics Group by 981.0% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock valued at $26,000 after acquiring an additional 206 shares during the period. Salomon & Ludwin LLC acquired a new stake in TransMedics Group during the third quarter valued at approximately $28,000. Harvest Fund Management Co. Ltd bought a new stake in shares of TransMedics Group in the 3rd quarter valued at approximately $29,000. Allworth Financial LP raised its holdings in shares of TransMedics Group by 74.3% in the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after buying an additional 113 shares in the last quarter. Finally, Optiver Holding B.V. lifted its position in shares of TransMedics Group by 248.1% during the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after buying an additional 191 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.